⦿ Executive Snapshot

• What: C4 Therapeutics reports Q1 2026 financial results and highlights progress in clinical trials for cemsidomide, aimed at treating multiple myeloma.
• Who: C4 Therapeutics, Roche, Andrew Hirsch (CEO).
• Why it matters: The advancement of cemsidomide represents a potential foundational therapy for multiple myeloma, addressing a critical need for new treatment options in a challenging cancer landscape.

⦿ Key Developments

• Cemsidomide is being evaluated in ongoing Phase 2 MOMENTUM trial and Phase 1b trial in combination with elranatamab, targeting relapsed refractory multiple myeloma.
• A new Phase 1b trial is set to initiate in 1H 2027, assessing cemsidomide with approved therapies, including dexamethasone and a CD38 antibody.
• C4 Therapeutics expanded its partnership with Roche through a new collaboration to develop degrader-antibody conjugates, receiving an upfront payment of $20 million.

⦿ Strategic Context

• Cemsidomide is positioned as a novel IKZF1/3 degrader, targeting a crucial mechanism in multiple myeloma, which has historically been challenging to treat effectively.
• The collaboration with Roche aligns with a broader trend in oncology towards combining targeted therapies to enhance treatment efficacy and patient outcomes.

⦿ Strategic Implications

• The advancements in cemsidomide's clinical trials may position C4 Therapeutics as a leader in the targeted protein degradation space, potentially increasing market share in oncology.
• Successful outcomes from ongoing trials could lead to accelerated approval pathways and expanded treatment options for patients with relapsed refractory multiple myeloma.

⦿ Risks & Constraints

• Potential risks include regulatory hurdles impacting the timeline for clinical trial results and market entry of new therapies.
• Competition from other biopharmaceutical companies developing similar treatments may affect C4's market position and partnership dynamics.

⦿ Watchlist / Forward Signals

• Key upcoming milestones include presentations at the EHA Congress in June 2026 and updates on trial progress in 2H 2026.
• Monitoring the initiation of the new Phase 1b trial in 1H 2027 will be critical in assessing the trajectory of cemsidomide's development and market entry potential.